Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

2(50.0%)

Phase 1

1(25.0%)

N/A

1(25.0%)

4Total

Phase 3(2)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT00916266Phase 1Completed

Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy

Role: collaborator

NCT01172353Phase 3Completed

Sodium Bicarbonate for Prevention of Contrast-Induced Nephropathy

Role: lead

NCT02029820Phase 3Unknown

RenalGuard System for Prevention of Contrast Induced Nephropathy

Role: lead

NCT01632501Not ApplicableCompleted

Safety and Efficacy of the Percutaneous Intervention Performed With Devices of a Single-brand

Role: lead

All 4 trials loaded